Product image #1 for Semaglutide (GLP-1s)

Semaglutide (GLP-1s)

    Take charge of your health with one of these powerful GLP-1 medications if your prescriber deems appropriate.

    Starting at $199

    Start online visit

    Group of women on the beach

    SEMAGLUTIDE BENEFITS

    Do more, age less

    • Semaglutide is the same active ingredient found in Wegovy® and Ozempic®
    • Ideal for adults with BMI >27
    • Use with reduced-calorie meal plan and exercise for best results
    • A healthy BMI is a key factor in longevity, reducing the risk of age-related diseases, heart attack, and stroke
    • Patients taking Wegovy® lost 15-20% of their body weight on average in 1 year*

    *In a 68- and 72-week clinical trial studying Wegovy® (2.4 mg) in patients without diabetes and with BMI ≥30, or BMI ≥27 with a weight-related condition, the average weight loss was 15% and 20%, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone).

    SEMAGLUTIDE

    Background and history

    • Mimics glucagon-like peptide (GLP-1), a hormone that regulates appetite and food intake
    • Revolutionary class of medications
    • Doses administered once weekly
    • Dosages titrated up over several months for maximum results
    Man with coffee and a shopping bag

    Is Semaglutide right for you?

    First, use our free wellness platform to find out what your BMI is.

    Next, find your BMI on the chart below to see if you’re within the indicated range for semaglutide treatment:

    BMIIs Semaglutide Right for Me?*
    24.9 or lessNo
    25.0 – 26.9Case-by-case**
    27.0 – 29.9Likely**
    30.0 or aboveLikely

    *The above chart is not meant for medical diagnosis purposes. Your prescriber will approve or disapprove a semaglutide prescription at their discretion after careful consideration of your unique health profile; approval is not guaranteed based on the above criteria.
    **Those with a BMI of 25-29 may be considered on a case-by-case basis after further review for the presence of additional weight-related medical issues.

    FAQs


    What is the difference between Wegovy®, Ozempic®, and Compounded Semaglutide?

    Ozempic® and Wegovy® are brand name semaglutide-based medications manufactured by Novo Nordisk, while Compounded Semaglutide is developed by our partner compounding pharmacies and features the same active ingredient as Ozempic® and Wegovy® (semaglutide). Another noticeable difference is that Compounded Semaglutide is self-administered via traditional syringes, while Ozempic® and Wegovy® feature a modern injection pen. Both Ozempic® and Wegovy® are currently on the FDA’s Drug Shortage List, but in the last quarter of 2022 alone, providers wrote over 9 million prescriptions for these medications, a number that has only grown since. When the demand for a medication goes up while the available supply goes down, the FDA allows compounding pharmacies to develop medications for the duration of an official shortage to avoid lapse in treatment. The FDA has not reviewed or approved of Compounded Semaglutide for any use, including AgelessRx compounded product, for safety, efficacy, or quality. When a drug is in shortage, as is now the case for Semaglutide, pharmacies may be authorized by the FDA to prepare a compounded version of that drug if they meet certain requirements in the Federal Food, Drug, and Cosmetic (FD&C) Act.


    Is Compounded Semaglutide safe?

    Compounded Semaglutide is made in an FDA-registered compounding pharmacy. Further, we have ensured that all formulations will only be compounded from semaglutide base, rather than its salt-based counterparts. Our partner pharmacies will continue to uphold our same standards of excellence for this and all other products, so that you can have the best outcomes possible.


    How do Semaglutide medications work?

    Semaglutide falls into a category of medications known as GLP-1 receptor agonists (GLP-1 RAs), which imitate the GLP-1 hormone to reduce the amount of glucose delivered into the bloodstream and encourage more insulin production from your pancreas. GLP-1 RAs also act on the digestive system to delay gastric emptying, thereby delaying the release of food from the stomach, and modulate brain activity to suppress appetite.

    See all FAQs

    Important safety information and common side effects


    Semaglutide medications should be used with a reduced-calorie meal plan and increased physical activity.

    Do not use Wegovy®, Ozempic®, or Compounded Semaglutide with other GLP-1 receptor agonist medicines, or any other products containing Semaglutide.

    Most common Semaglutide side effects

    The most common side effects of Semaglutide (GLP-1) medications include nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (belching), hypoglycemia (low blood sugar) in patients with type 2 diabetes, flatulence (gas buildup), gastroenteritis (an intestinal infection) and gastroesophageal reflux disease (a type of digestive disorder).

    The above is only a summary. For a full list of possible side effects, and other important safety information, please reference the Mayo Clinic’s list of Semaglutide side effects.

    Other important safety information

    Wegovy® is FDA approved to treat weight loss in adults with a BMI of 30 or greater. It’s also approved for those with a BMI of 27 or greater who have a weight-related medical condition.

    Ozempic® is FDA approved to treat type 2 diabetes.

    The compounding of Semaglutide is temporarily allowed by the FDA on an emergency basis while Semaglutide-based medications are on the FDA’s Drug Shortage List. Compounded Semaglutide has not been evaluated by the FDA, and is not FDA approved for weight loss or type 2 diabetes.

    Approval for treatment is not guaranteed. Eligibility and approval are always at the discretion of the prescriber, who will determine eligibility based on an assessment of your complete health profile.

    Do not use Wegovy®, Ozempic®, or Compounded Semaglutide if you are allergic to Semaglutide or any of its ingredients.

    Do not use Wegovy®, Ozempic®, or Compounded Semaglutide if you are currently pregnant, breastfeeding or plan to become pregnant or breastfeed.

    Do not use Wegovy®, Ozempic®, or Compounded Semaglutide if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC), or if you have an endocrine system condition called multiple endocrine neoplasia syndrome type 2 (MEN 2).

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Semaglutide (GLP-1) medications may affect the way some medicines work, and some medicines may affect the way Semaglutide works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin.

    Please visit Ozempic.com or Wegovy.com for a full list of important safety information for these medications.

    For a full list of important safety information for Compounded Semaglutide, please visit the FDA’s Compounded Semaglutide resources.

    Note: These products alone are not intended to diagnose, treat, cure, or prevent any disease. Please consult a medical professional to determine whether or not Semaglutide (GLP-1) medications could be appropriate for you.